The EpiPen buyers leading price-gouging litigation against two top drugmakers secured final approval Wednesday from a federal judge in Kansas for their $345 million settlement with
Judge Daniel D. Crabtree signed off on the agreement, which resolves class action antitrust claims brought against Pfizer in the U.S. District Court for the District of Kansas on behalf of “end payers” like insurers, pension funds, and consumers. The deal includes a $115 million payday for their attorneys.
The settlement doesn’t directly affect the claims against Mylan or ...